Our relentless dedication to accuracy, timeliness and regulatory rigor enables your therapeutic innovations to reach patients faster.
BioAgilytix Secures Significant New Investment from Global Investor Cinven to Fuel Continued Long-Term Growth
Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Biomarkers
Immunogenicity
Pharmacokinetics & Pharmacodynamics (PK/PD)
Cell-Based Assays
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for therapeutics innovation.
Biosimilars
Gene Therapy
Antibody Drug Conjugates (ADCs)
Immuno-oncology
In association with Oxford Global, this webinar features an expert panel to discuss our work with potency assays for gene and cell therapy products. As the number of gene and cell therapy products in development continues to increase, so has BioAgilytix’s focus on their importance. Hear from our team of experts that are helping our customers pursue the opportunities of this compelling therapeutic strategy by leveraging our deep NAb assay capabilities and vast experience with a variety of viral vectors.
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
October 26, 2021BioAgilytix Adds Extensive Capabilities with the Acquisition of MicroConstants and 360biolabs®️
September 29, 2021Flow Cytometry in Bioanalysis: Application, Utility and Recent Advancements
November 17, 2021BioAgilytix Secures Significant New Investment from Global Investor Cinven to Fuel Continued Long-Term Growth
October 14, 2021BioAgilytix Closes Acquisition of Australia-based 360biolabs®
August 6, 2020Analytical Assays Determine Biosimilar Product Quality
December 2, 2019Immunogenicity Assessment of Gene Therapy Compounds
Platforms
Services
